DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 19-898/S-058

Bristol-Myers Squibb Company
Attention: Porter P. Layne, Ph.D.
Group Director, Metabolic/Endocrine Drug Products
P.O. Box 4000
Princeton, NJ 08543-4000

Dear Dr. Layne:

Please refer to your supplemental new drug application dated March 30, 2005, received March 31, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Pravachol (pravastatin sodium) Tablets.

This "Changes Being Effected" supplemental new drug application provides for changes to the **DESCRIPTION**, **INDICATIONS AND USAGE**, **CONTRAINDICATIONS**, **WARNINGS**, **ADVERSE REACTIONS**, and **HOW SUPPLIED** sections of the Pravachol package insert. The changes are as follows:

To the **DESCRIPTION** section, the word "new" was deleted from the first sentence.

To the **INDICATIONS AND USAGE,** *Hyperlipidemia* subsection, "Table 7" was added to the title of the NCEP Treatment guidelines table.

To the **CONTRAINDICATIONS** section, the second paragraph was changed to read:

> "Active liver disease or unexplained, persistent elevations of serum transaminases (see **Warnings**)."

To the **WARNINGS,** ***Skeletal Muscle*** subsection, the third sentence was changed to read:

> "Myopathy, defined as muscle aching or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values to greater than 10 times the upper limit of normal, was rare (<0.1%) in pravastatin clinical trials."

To the **ADVERSE REACTIONS,** ***Postmarketing Experience, Hypersensitivity***, "angioedema" was added to the list of hypersensitivity reactions.

To the **ADVERSE REACTIONS, Postmarketing Experience,** ***Laboratory Abnormalities***, "elevated alkaline phosphatase and bilirubin" was replaced with "Liver Function Test abnormalities".

To the **HOW SUPPLIED, 80mg tablets** section, the first sentence was changed to read:

"Yellow, oval-shaped tablet with "BMS" on one side and "80" on the other side."

We completed our review of this supplemental new drug application. It is approved, effective on the date of this letter, for use as recommended in final printed labeling (FPL) submitted on March 30, 2005. However, we recommend that "LFT" be spelled out as "Liver Function Test" under **ADVERSE REACTIONS, Postmarketing Experience, *Laboratory Abnormalities***, as this is the one and only listing of this abbreviation in the label. Revise your labeling to include this information at your next printing and report this change in your annual report.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division/ the Division of Division of Metabolic and Endocrine Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Margaret Simoneau, M.S., R.Ph., Regulatory Project Manager, at (301) 827-6411.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Mary Parks
7/6/05 09:41:16 AM
for Dr. Orloff